lung-cancer

PET/CT-guided approach shows which NSCLC patients can skip radiotherapy after immunotherapy response.

Retrospective study of 73 NSCLC patients who didn't undergo surgery after neoadjuvant chemoimmunotherapy found no significant differences in PFS or OS between those who received radiotherapy vs. not. However, in patients with PET/CT SUVmax ≤4, RT did not improve PFS. For SUVmax ≥8, RT showed…

PET/CT-guided approach shows which NSCLC patients can skip radiotherapy after immunotherapy response.

Key Findings

No significant PFS or OS difference between RT and non-RT groups overall
In patients with PET/CT SUVmax ≤4, radiotherapy may be safely omitted
For SUVmax ≥8, radiotherapy showed significant PFS benefit
PET/CT plays critical role in guiding subsequent treatment selection
73 NSCLC patients who did not undergo surgery after NACI analyzed

Implications

PET/CT SUVmax could guide radiotherapy decisions in NSCLC patients who don't proceed to surgery after neoadjuvant immunotherapy. Low SUVmax patients may safely avoid radiotherapy.

Caveats

Small retrospective study (n=73); abstract-only. Limited follow-up. Selection bias inherent in treatment decision data. Prospective validation needed.

Source: Thoracic cancer — 2026-04-01

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.

PET/CT-guided approach shows which NSCLC patients can skip radiotherapy after immunotherapy response.

Key Findings

Implications

Caveats

Read more

Landmark DCIS trial, CRC microbiome & AML combos

Colorectal Cancer Microbiome Discovery Platform

GBM Tumor Microenvironment Drug Target Atlas

BET Inhibitor Target Selectivity Database